Cencora (NYSE:COR) Stock Price Down 4.6% – Should You Sell?

Cencora, Inc. (NYSE:COR) shares fell 4.6% during mid-day trading on Wednesday . The stock traded as low as $334.31 and last traded at $334.6990. Approximately 1,750,650 shares traded hands during mid-day trading, an increase of 13% from the average session volume of 1,543,520 shares. The stock had previously closed at $350.67.

Wall Street Analyst Weigh In

COR has been the subject of a number of recent research reports. Weiss Ratings downgraded shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Wells Fargo & Company raised their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. TD Cowen increased their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Trading Down 4.5%

The business has a fifty day simple moving average of $338.10 and a 200-day simple moving average of $308.78. The firm has a market cap of $64.93 billion, a price-to-earnings ratio of 42.12, a PEG ratio of 1.71 and a beta of 0.63. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the business earned $3.34 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s payout ratio is presently 30.19%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 46,640 shares of company stock valued at $14,099,338. 10.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently modified their holdings of COR. Vestcor Inc lifted its holdings in Cencora by 0.5% during the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after purchasing an additional 28 shares during the last quarter. Cornerstone Wealth Group LLC raised its position in shares of Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after purchasing an additional 30 shares during the period. Security Financial Services INC. lifted its stake in shares of Cencora by 2.6% during the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after buying an additional 33 shares in the last quarter. Vermillion & White Wealth Management Group LLC boosted its holdings in Cencora by 31.4% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company’s stock worth $43,000 after buying an additional 33 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC grew its stake in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.